|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | MONOCLONAL ANTIBODIES: A NOVEL APPROACH FOR THE TREATMENT OF EARLY ALZHEIMER'S |
| Authors Name: | JAYASHEELA .S. HIREMATH , AHM VISWANATHA SWAMY , ANCHU S P , JOBNA MERENA ABRAHAM , SHRUTHI SREEKUMAR |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_190919
|
| Published Paper Id: | IJNRD2304195 |
| Published In: | Volume 8 Issue 4, April-2023 |
| DOI: | http://doi.one/10.1729/Journal.33770 |
| Abstract: | Alzheimer’s is a progressive neurodegenerative disorder primarily characterized in the form of dementia. The underlying pathology of this condition is defined by deposition of beta amyloids and neurofibrillary tangles. No drug has shown prevention or cure of this condition. The Amyloid hypothesis suggests progression of Alzheimer’s could be halted by removing beta amyloids in brain. Thus, monoclonal antibodies (mAbs) have become an area of focus on research as disease modifying therapies in Alzheimer’s. Several clinical trials are going on but some of them have proven that mAbs in early Alzheimer’s could reduce the clinical decline of behavioral and cognitive function. US FDA has provided approval for Aducanumab and Lecanemab for the treatment of early Alzheimer’s through accelerated approval pathway. This review focuses the safety and efficacy profiles of mAbs including Aducanumab, Lecanemab, Ganeteneumab, Crenezumab, Donanezumab, Bapineuzumab and Solanezumab. Since there was lack of post-marketing surveillance, the clinical benefit of these medications is yet to be confirmed. In this review, we discuss the potential disease-modifying agents studied in clinical trials and update the information of mAbs that are still under clinical evaluation. |
| Keywords: | Alzheimer’s disease, disease-modifying therapies, monoclonal antibodies, clinical trials, Lecanemab, Aducanumab |
| Cite Article: | "MONOCLONAL ANTIBODIES: A NOVEL APPROACH FOR THE TREATMENT OF EARLY ALZHEIMER'S", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 4, page no.b706-b715, April-2023, Available :http://www.ijnrd.org/papers/IJNRD2304195.pdf |
| Downloads: | 000118757 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2304195 Registration ID: 190919 Published In: Volume 8 Issue 4, April-2023 DOI (Digital Object Identifier): http://doi.one/10.1729/Journal.33770 Page No: b706-b715 Country: HUBBALLI, DHARWAD, KARNATAKA, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2304195 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2304195 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn